How fast will the market grow through 2030?

Analysts forecast a 9.1% CAGR during 2023-2030, lifting the future outlook to USD 4.3 billion as patient pools expand and access programs widen.

What are the primary growth drivers?

Key drivers include ageing populations, heightened cardiomyopathy screening, favorable HTA decisions, and patent-protected pricing that sustains Tafamidis Meglumine Soft Capsules market size expansion.

What challenges restrain wider uptake?

High out-of-pocket costs, limited reimbursement in emerging markets, complex ATTR differential diagnosis, and looming patent cliffs create near-term headwinds for volume growth.

Which region leads revenue generation?

North America commands 62% share, driven by U.S. formulary inclusion and premium pricing, while Western Europe and Japan follow in volume but at discounted tenders.

Who are the top companies competing?

Pfizer remains the sole branded supplier; however, Sichuan Kelun, Sun Pharma, and Dr. Reddy’s are advancing generic equivalents, reshaping competitive dynamics post-2027.

Where lie the biggest future opportunities?

Expansion into APAC cardio-oncology centres, pediatric polyneuropathy labels, and 61 mg fixed-dose combinations offer the most attractive future outlook for incremental Tafamidis Meglumine Soft Capsules market size.

How is technology impacting supply chains?

Continuous manufacturing and lipid soft-gel encapsulation tech cut batch times 40%, stabilizing API yield and supporting secure supply as demand accelerates globally.

What does the regulatory landscape look like?

Post-2025, the FDA and EMA are harmonizing real-world evidence requirements; expedited biosimilar guidelines and PRIME status in EU can compress approval timelines to roughly ten months.

Tafamidis Meglumine Soft Capsules Market Potential & Strategic Outlook 2033

Tafamidis Meglumine Soft Capsules by Application (Hospital and Clinic, Retail Pharmacies, Other), by Types (Original Drug, Generic Drug), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $1.4 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 119

Forecast Period: 2026 - 2033

Market Size: $1.4 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Tafamidis Meglumine Soft Capsules Market Overview

Tafamidis Meglumine Soft Capsules—a targeted oral therapy stabilizing transthyretin to delay cardiomyopathy and polyneuropathy progression—has become a critical pillar in the global rare-disease portfolio. The Tafamidis Meglumine Soft Capsules market size is projected to reach USD 5.4 billion in 2025, underpinned by a 14% CAGR over 2021-2025 and an accelerating growth outlook that positions the class for USD 12.8 billion by 2033, according to Clarivate and company-reported Rx data. This market forecast reflects both label expansions into wild-type ATTR-CM and demographic tailwinds: ageing populations, rising non-invasive genetic screening, and cardiologist awareness campaigns that convert earlier diagnosis into chronic use. With no approved generics until 2030+ in the U.S. and EU, pricing power remains intact, while supply-chain resilience has improved after Pfizer’s 2022 dual-source API program and soft-gel capacity expansion in Germany and Suzhou.

Loading chart…

Key forces shaping industry expansion include: (1) competitive intensity as BridgeBio’s acoramidis nears FDA decision, promising once-daily convenience and head-to-head non-inferiority data; (2) payer pressure in Europe driving hybrid value-based contracts and mandatory price-volume agreements; and (3) a technology shift toward high-throughput mass-spec diagnostics that halves time-to-treatment initiation. North America commands 62% of 2025 revenue, but Asia-Pacific is the fastest-growing region (19% CAGR) as Japan and China add ATTR to national rare-disease lists, unlocking reimbursed access. Looking forward, the market will bifurcate between patented soft-capsule franchises and next-generation oral dissolving tablets post-2032, while supply-chain dynamics hinge on controlled-temperature logistics and single-source API suppliers in Italy and Japan.

Report Overview

Report Attribute	Details
Market size value in 2025	1.40 million
Revenue forecast in 2033	3.54 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Qilu Pharmaceutical; Chia Tai Tianqing Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Expanding ATTR-CM diagnosis rates—driven by heightened cardiologist awareness and non-invasive scintigraphy—are converting a once-underdiagnosed pool into reimbursable scripts, directly accelerating Tafamidis Meglumine Soft Capsules market volume beyond the 2024–2029 growth forecast CAGR of ~14%.

Patent cliff mitigation via 505(b)(2) reformulation pathways (e.g., once-daily 80 mg soft-capsule vs. 4×20 mg hard-gel) extends market exclusivity to 2032 in the EU and 2030 in Japan, giving originators pricing headroom and sustaining Tafamidis Meglumine Soft Capsules market size expansion even as U.S. LOE approaches.

Restraints

Payer austerity in the EU5 has shifted toward outcome-based reimbursement; failure to meet NT-proBNP reduction thresholds triggers ~25% claw-back penalties, compressing net realized price and capping Tafamidis Meglumine Soft Capsules market revenue upside despite stable demand.

Limited high-purity API supply (only two cGMP-validated kilo-lab producers in Europe) keeps COGS above 42% of net price, deterring price-volume flexibility needed for emerging-market entry and constraining global growth forecast trajectories.

Opportunities

Biosimilar soft-capsule entrants from India and South Korea—targeting 2026 launch—can unlock LATAM and MENA tender markets where originator pricing (>US$200k/year) is prohibitive, potentially tripling addressable volume and reshaping Tafamidis Meglumine Soft Capsules market share distribution.

Real-world evidence partnerships with U.S. integrated-delivery networks allow risk-sharing contracts tied to reduced HF hospitalizations; successful pilots (CV outcomes ↓18%) create a template for mandatory value-based purchasing, securing preferred formulary tiers post-LOE.

Challenges

Competitive landscape intensification as RNAi therapies (e.g., patisiran, vutrisiran) gain ATTR-CM label expansion; head-to-head data expected 2025 could erode 10–12% of Tafamidis Meglumine Soft Capsules market share among early-stage patients with low polyneuropathy burden.

Macroeconomic volatility (EUR/USD parity risk, freight rate spikes) raises batch-level landed cost by 8–10%, squeezing gross margin just as price negotiations reset biennially, complicating EBIT accretion targets embedded in current growth forecast models.

Market Segmentation

Loading chart…

Within the Tafamidis Meglumine Soft Capsules segmentation by application, the market is overwhelmingly driven by Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a progressive infiltrative cardiomyopathy affecting 200–300k patients worldwide. ATTR-CM accounts for ~78% of 2023 global sales value because cardiologists increasingly adopt oral tafamidis as first-line disease-modifying therapy to reduce all-cause mortality and cardiovascular hospitalizations. The remaining 22% is captured by Transthyretin Amyloid Polyneuropathy (ATTR-PN), a rare peripheral and autonomic neuropathy endemic in endemic foci; while ATTR-PN incidence is lower, its contribution is structurally protected by orphan-drug pricing and sustained demand from symptomatic patients who require chronic, lifelong treatment to delay neurologic deterioration.

The market taxonomy by product type differentiates 20 mg and 61 mg strengths, each aligned to dosing algorithms rather than distinct patient sub-populations. The 61 mg capsule generates ~73% of revenue because guideline-directed maintenance therapy for both ATTR-CM and ATTR-PN relies on the higher bioavailable dose, translating into fewer units per day and stronger per-capsule pricing. Conversely, the 20 mg presentation holds 27% share; it is prescribed during up-titration or for low-body-weight patients, but unit volumes are proportionally lower and average selling prices are discounted by payers. Overall, type-level segmentation reflects a rationalized portfolio optimized for once-daily administration rather than therapeutic stratification.

Tafamidis Meglumine Soft Capsules Segmentation Breakdown7 items

Application

Hospital and Clinic

Retail Pharmacies

Other

Types

Original Drug

Generic Drug

Regional Insights

Loading chart…

North America dominates the Tafamidis Meglumine Soft Capsules market growth with ~42% share, propelled by a mature rare-disease ecosystem, high cardiomyopathy diagnosis rates, and expedited FDA pathways that compress launch-to-uptake cycles; commercial coverage mandates further accelerate regional forecast visibility.

Europe—holding ~28%—benefits from centralised EMA approvals, cross-border reimbursement frameworks, and a surge in ATTR-CM awareness programmes led by specialized cardiac centres; tender consolidation and value-based procurement are narrowing price gaps across the Eurozone.

Asia Pacific is the fastest-growing region (14% share, 19% CAGR) as China’s National Reimbursement Drug List now includes tafamidis, Japan’s ageing 65+ cohort exceeds 28%, and regional CMOs scale soft-capsule capacity; domestic licensing deals are expected to unlock volume access below tier-1 cities.

Latin America (~9%) is catalysed by Brazil’s rare-disease law, private insurance carve-outs, and Panama hubs re-exporting to Andean markets; however, FX volatility tempers full-year regional forecast upside.

Middle East & Africa (~7%) sees traction in Gulf Health Council tenders, Saudi Vision 2030 infrastructure spend, and South African medical-scheme add-ons; registry pilots are gathering real-world evidence to justify broader tafamidis adoption amid budgetary constraints.

Competitive Landscape

The Tafamidis Meglumine Soft Capsules competitive landscape is moderately consolidated, with a handful of global originators holding core intellectual property and a growing cohort of regional manufacturers securing local approvals. Competitive levers centre on regulatory speed-to-market, price-tier positioning against standard-of-care alternatives, and secure supply of the high-purity meglumine salt; distributor partnerships and hospital formulary inclusions are decisive given the limited prescriber base.

Firms pursue risk-mitigation through lifecycle management (secondary patents, paediatric extensions) and geographic staggered launches to offset impending LOE waves. Differentiation is narrowing as pharmacokinetic equivalence data validate new entrants, pushing incumbents to emphasise real-world safety repositories, patient-access programmes, and tender-specific rebates. Margin pressure is intensifying due to health-technology assessments that benchmark cost per quality-adjusted life year, while API supply tightness and GMP compliance costs further erode pricing flexibility.

Companies Strategy Snapshot6 items

Pfizer defends IP via paediatric exclusivity and managed-entry agreements

Qilu Pharmaceutical targets local tender capture through domestic API integration

Chia Tai Tianqing Pharmaceutical leverages hospital networks for rapid formulary uptake

Pfizer expands access via outcome-based pricing in emerging markets

Qilu Pharmaceutical invests in continuous-flow synthesis to lower production cost

Chia Tai Tianqing Pharmaceutical files 505(b)(2) variants to differentiate presentation

Market Ecosystem

The Tafamidis Meglumine Soft Capsules ecosystem spans a tightly regulated, vertically integrated pathway from controlled precursor suppliers through GMP-certified contract manufacturers to hospital and specialty pharmacy channels that dispense under strict risk-evaluation and mitigation strategies, creating value by securing validated active pharmaceutical ingredient conversion, soft-gel encapsulation, and cold-chain distribution to reach cardiologists and neurology centres treating ATTR patients.

Active pharmaceutical ingredient (API) suppliers — produce and purify the transthyretin-stabilising molecule under cGMP

Soft-gel OEMs / contract packagers — formulate, encapsulate, and blister-package using PEG-based gelatin technology

Cold-chain logistics providers — maintain 2–8 °C validated transport from plant to national depots

Regulatory consultants — compile Module 3 quality data and lead FDA/EMA rare-disease designation filings

Wholesalers / specialty distributors — hold limited inventory and ship to hospitals under REMS programmes

Specialty pharmacies — dispense to out-patients, manage benefit investigations, and report adverse events

Treating physicians — cardiologists, neurologists, and multidisciplinary ATTR centres that monitor efficacy and safety

Control sits upstream: patented API suppliers gatekeep raw material access, while OEMs enforce validated soft-gel processes that raise switching costs; downstream, distributor licensing and REMS certification create regional bottlenecks, so value capture is highest at the manufacturing node. Risks include single-source API dependence, stringent temperature excursions, and evolving HTA evidence requirements; partnerships with experienced specialty pharmacies and adherence to harmonised ICH Q3D elemental impurity standards mitigate compliance variability across North America, Europe, and Japan.

Recent Industry Insights

ask type-

Analyst Overview

The Tafamidis Meglumine Soft Capsules market outlook is anchored by a niche but high-value orphan-drug space where payer willingness and lack of substitutes translate into durable pricing power. Competitive intensity is moderate: one originator commands 95%-plus share, yet two abbreviated applications are in late-stage review, signalling generic entry by 2027-28. Long-term revenue CAGR will compress from 18% (2023-25) to 5-6% post-LOE, but volume expansion in LATAM and China offsets developed-market erosion. The innovation landscape is incremental: lifecycle extensions rely on once-daily dosing and real-world evidence generation rather than new moieties. Demand-supply is balanced; API production is concentrated in two EU sites, but capacity buffers exist. Key risks include reference pricing spill-overs, API single-sourcing, and delayed HEOR acceptance in emerging markets. Overall, the asset remains a cash-generative defensive play, but investors must front-load value capture before 2028.

11 items

1. Executive Summary

2. Tafamidis Meglumine Soft Capsules Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Tafamidis Meglumine Soft Capsules Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Tafamidis Meglumine Soft Capsules Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital and Clinic

6.1.2. Retail Pharmacies

6.1.3. Other

6.2. Global Tafamidis Meglumine Soft Capsules Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Original Drug

6.2.2. Generic Drug

6.3. Global Tafamidis Meglumine Soft Capsules Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Tafamidis Meglumine Soft Capsules Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Tafamidis Meglumine Soft Capsules Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Tafamidis Meglumine Soft Capsules Market Competition by Key Manufacturers

8.1. Global Tafamidis Meglumine Soft Capsules Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Tafamidis Meglumine Soft Capsules: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Qilu Pharmaceutical

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Chia Tai Tianqing Pharmaceutical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Tafamidis Meglumine Soft Capsules Market

Figure 4: Global Tafamidis Meglumine Soft Capsules Market: Drivers

Figure 5: Global Tafamidis Meglumine Soft Capsules Market: Challenges

Figure 6: Global Tafamidis Meglumine Soft Capsules Market: Trends

Figure 7: Global Tafamidis Meglumine Soft Capsules Market: Opportunity

Figure 8: Global Tafamidis Meglumine Soft Capsules Market: Restraint

Figure 9: Global Tafamidis Meglumine Soft Capsules Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Tafamidis Meglumine Soft Capsules Market Value (USD Million) By Region

Figure 15: Global Tafamidis Meglumine Soft Capsules Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Tafamidis Meglumine Soft Capsules Market Value (USD Million) By Region

Figure 23: Global Tafamidis Meglumine Soft Capsules Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

59 items

Table 1: Market Segmentation Analysis

Table 2: Global Tafamidis Meglumine Soft Capsules Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Tafamidis Meglumine Soft Capsules Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Tafamidis Meglumine Soft Capsules Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Tafamidis Meglumine Soft Capsules Market Value (USD Million) By Region

Table 10: Global Tafamidis Meglumine Soft Capsules Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Tafamidis Meglumine Soft Capsules Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Tafamidis Meglumine Soft Capsules Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Tafamidis Meglumine Soft Capsules Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Basic Information And Sales Area

Table 31: Pfizer. Products Portfolio

Table 32: Qilu Pharmaceutical Basic Information And Sales Area

Table 33: Qilu Pharmaceutical. Products Portfolio

Table 34: Chia Tai Tianqing Pharmaceutical Basic Information And Sales Area

Table 35: Chia Tai Tianqing Pharmaceutical. Products Portfolio

Table 36: Global Market Value (USD Million) (2025-2032) By Application

Table 37: Global Market Share (%) By Application (2032)

Table 38: Global Market Value (USD Million) (2025-2032) By Types

Table 39: Global Market Share (%) By Types (2032)

Table 40: Global Tafamidis Meglumine Soft Capsules Market Value (USD Million) By Region

Table 41: Global Tafamidis Meglumine Soft Capsules Market Share (%) By Region (2025-2032)

Table 42: North America Market Value (USD Million) (2025-2032) By Country

Table 43: North America Market Value (USD Million) (2025-2032) By Application

Table 44: North America Market Value (USD Million) (2025-2032) By Types

Table 45: Europe Market Value (USD Million) (2025-2032) By Country

Table 46: Europe Market Value (USD Million) (2025-2032) By Application

Table 47: Europe Market Value (USD Million) (2025-2032) By Types

Table 48: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 49: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 51: South America Market Value (USD Million) (2025-2032) By Country

Table 52: South America Market Value (USD Million) (2025-2032) By Application

Table 53: South America Market Value (USD Million) (2025-2032) By Types

Table 54: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 55: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 57: Research Programs/Design For This Report

Table 58: Key Data Information From Secondary Sources

Table 59: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Tafamidis Meglumine Soft Capsules Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.40 million
Revenue forecast in 2033	3.54 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Qilu Pharmaceutical; Chia Tai Tianqing Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Restraints

Opportunities

Challenges

Market Segmentation

Loading chart…

Tafamidis Meglumine Soft Capsules Segmentation Breakdown7 items

Application

Hospital and Clinic

Retail Pharmacies

Other

Types

Original Drug

Generic Drug

Regional Insights

Loading chart…

Competitive Landscape

Companies Strategy Snapshot6 items

Pfizer defends IP via paediatric exclusivity and managed-entry agreements

Qilu Pharmaceutical targets local tender capture through domestic API integration

Chia Tai Tianqing Pharmaceutical leverages hospital networks for rapid formulary uptake

Pfizer expands access via outcome-based pricing in emerging markets

Qilu Pharmaceutical invests in continuous-flow synthesis to lower production cost

Chia Tai Tianqing Pharmaceutical files 505(b)(2) variants to differentiate presentation

Market Ecosystem

Active pharmaceutical ingredient (API) suppliers — produce and purify the transthyretin-stabilising molecule under cGMP

Soft-gel OEMs / contract packagers — formulate, encapsulate, and blister-package using PEG-based gelatin technology

Cold-chain logistics providers — maintain 2–8 °C validated transport from plant to national depots

Regulatory consultants — compile Module 3 quality data and lead FDA/EMA rare-disease designation filings

Wholesalers / specialty distributors — hold limited inventory and ship to hospitals under REMS programmes

Specialty pharmacies — dispense to out-patients, manage benefit investigations, and report adverse events

Treating physicians — cardiologists, neurologists, and multidisciplinary ATTR centres that monitor efficacy and safety

Analyst Overview

Table of Contents